The New York Academy of Medicine, 1216 Fifth Avenue at 103rd Street, New York, NY 10029
2:45 pm - 9:00 pm (Includes buffet dinner)
Free, but advance registration is required
2020 Alison Norris Symposium: Social Determinants of Kidney Health
The Alison Norris Symposia of the New York Academy of Medicine have been dedicated to enhancing the ability of renal practitioners to engage with the personal, social, and economic realities that our patients face. The 2020 symposium with be the fifth in the series and will examine socio-economic challenges to kidney care. The first half of the program will examine the health impact of race, ethnicity, and poverty from a national perspective. In the second half of the program, we will drill down to see how these issues manifest themselves in New York City and in individual exam room encounters. Providers of kidney care should come away with greater understanding of the context in which our patients are receiving information and making their healthcare decisions.
L. Ebony Boulware, MD, MPH, is the Eleanor Easley Chair in the School of Medicine, Chief of the Division of General Internal Medicine in the Department of Medicine, Vice Dean for Translational Science, and Associate Vice Chancellor for Translational Research at Duke University. She is a general internist and clinical epidemiologist. She studies mechanisms to improve the quality and equity of healthcare and health outcomes for individuals and populations affected by chronic health conditions including kidney disease and hypertension. Her work explores how the characteristics of individuals, health care providers, and health care organizations contribute to individuals’ health, and importantly, inequities in health. As Director of the Duke Clinical and Translational Science Institute, she helps scientists at Duke and across the nation speed the pace at which their scientific discoveries reach individuals, their families, and their communities. Dr. Boulware received an AB from Vassar College, an MD from Duke University, and a MPH from the Johns Hopkins Bloomberg School of Public Health. Her research has been funded by numerous organizations, including the National Institutes for Health, the Patient Centered Outcomes Research Institute, the Health Resources and Services Administration, and the Agency for Health Care Research and Quality. Dr. Boulware is an elected member of the American Society for Clinical Investigation and the National Academy of Medicine.
Lilia Cervantes, MD, is Associate Professor in the Department of Medicine and Office of Research at Denver Health, and in the Division of General Internal Medicine and Hospital Medicine, University of Colorado Medical Anschutz Campus in Aurora, Colorado. She has worked at Denver Health, the safety-net hospital, for over 10 years as an internal medicine hospitalist. Dr. Cervantes’ personal reality as a first-generation, English-as-a-second-language Latina has directly informed her deep commitment to becoming a physician researcher and caring for the underserved. Dr. Cervantes has dedicated her career to both creating a healthcare workforce that is diverse as well as conducting research to improve person-centered and clinical outcomes among undocumented and documented Latinos on dialysis. The catalyst for her interest in improving outcomes for Latino patients with End-Stage Kidney Disease (ESKD) was a former undocumented Latina patient with ESKD who struggled with emergency-only hemodialysis and ultimately died. Dr. Cervantes demonstrated that undocumented immigrant patients with ESKD reliant on emergency-only hemodialysis suffer physical and psychosocial distress and have a higher mortality compared to patients with that receive standard thrice-weekly hemodialysis. In 2019, as a result of Dr. Cervantes’ research and stakeholder engagement, Colorado Medicaid opted to include the diagnosis of "End-Stage Kidney Disease" in the definition of "emergency medical condition," thereby expanding access to standard dialysis to undocumented immigrants. Dr. Cervantes’ research has directly informed policy and saved the lives of undocumented immigrants with ESKD. In addition to her work with the undocumented ESKD community, Dr. Cervantes is developing culturally tailored interventions that will address the social challenges faced by poor patients on dialysis. Dr. Cervantes received her medical degree and completed her internal medicine residency at the University of Colorado School of Medicine.
Daniel Cukor, PhD, is currently the Director of Behavioral Health at The Rogosin Institute. He received his PhD in Clinical Health Psychology from Ferkauf Graduate School (2002). The bulk of his research has focused on psychosocial issues in patients with end stage renal disease. His current clinical and research interests are focused on depression, anxiety, sleep difficulty, pain and caregiver burden in patients with chronic renal disease.
Paul L Kimmel, MD, MACP, FRCP, FASN, is a Clinical Professor of Medicine, at George Washington University in Washington, DC. Currently he is Senior Advisor to the Director of the Division of Kidney Uologic and Hematologic Diseases at the National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health. Previously, Dr. Kimmel was a faculty member at the University of Pennsylvania, served as Professor, and Director of the Division of Renal Diseases and Hypertension at George Washington University, and was Director of Education at the American Society of Nephrology. His interests span psychosocial adaptation to chronic renal disease, HIV-associated renal diseases, clinical genetics of common kidney disease, inflammation in patients with kidney disease, and interrelationships between acute kidney injury and chronic kidney disease. He is interested in the long-term association of acute kidney injury, and the development of chronic kidney disease in patients with different genetic characteristics, and the effects of APOL1 variants on outcomes in African-Americans receiving kidney transplantation. He participated in clinical trials in hypertension and nephrology including MDRD, HEMO, SPRINT, ASCEND and the Novel Therapies Hemodialysis Consortium, as well as the APOLLO study and the newly constituted HOPE study, to decrease opioid prescription in hemodialysis patients. In 2019, Dr. Kimmel was the recipient of the American Society of Nephrology’s Belding Scribner Award. He graduated from Yale College and New York University School of Medicine, finishing his internal medicine residency at Bellevue Hospital in New York City and nephrology fellowship at the University of Pennsylvania in Philadelphia.
Keith Norris, MD, PhD, is an internationally recognized clinician scientist and health policy leader who has been instrumental in shaping national health policy and clinical practice guidelines for chronic kidney disease (CKD). He has made major contributions to diversity, equity and inclusion while addressing disparities in contemporary society. After leaving Cornell at the age of 19, he attended Howard University College of Medicine. Upon graduation he was inducted into the Alpha Omega Alpha medical honor society. From 1983-86, he trained in nephrology at the combined West Los Angeles Veterans Administration-UCLA program where he trained under the Late Dr. Jack Coburn. In addition to being board certified in internal medicine and nephrology, he is an American Society of Hypertension, Specialist in Clinical Hypertension. In 2014 he received his doctorate in religious, spiritual and metaphysical philosophy. After serving as Executive VP for Research and Health Affairs and Interim President at Charles Drew University he returned to UCLA as a Professor of Medicine and Co-Director of the Clinical and Translational Science Institute Community Engagement Research Program and newly appointed as the Department of Medicine Executive Vice Chair for Diversity, Equity and Inclusion. His research interests focus on hypertension and CKD in disadvantaged populations. He was a Principal Investigator for the multi-site NIH funded African American Study of Kidney Disease and Hypertension (AASK) and the AASK Cohort Study, the largest comparative drug intervention trial focusing on renal outcomes conducted in African Americans. Dr. Norris has received numerous honors and awards from students, peers, community, and professional organizations. He has co-authored over 400 articles in peer-reviewed journals and book chapters, is a co-editor for the 2017 book Chronic Kidney Disease in Disadvantaged Populations. He serves as the Editor-in-Chief Emeritus of the international journal, Ethnicity and Disease. He also serves as a member of the editor board for the Journal of the American Society of Nephrology and the Clinical Journal of the American Society of Nephrology.
Neil Powe, MD, MPH, MBA, is the Chief of Medicine at the Priscilla Chan and Mark Zuckerberg San Francisco General Hospital and the Constance B. Wofsy Distinguished Professor and Vice-Chair of Medicine at the University of California San Francisco where he serves as administrative leader of the Department of Medicine and oversees 14 divisions, more than 700 employees engaged in clinical practice, medical education and research. Prior to his role at UCSF, Dr. Powe was the James F. Fries University Distinguished Professor at the Johns Hopkins University where he directed the Welch Center for Prevention, Epidemiology and Clinical Research and the Training, Education and Career Development Programs for the Clinical and Translational Science Institute. His interests are in improving discovery, education and clinical practice in medicine, making academic organizations function better, enhancing scholarship and multidisciplinary collaboration, and developing future talent and leadership in the health professions. He has a particular interest in cultivating young scientists who are addressing major problems in science, health and healthcare delivery. His primary intellectual pursuits involve kidney disease patient-oriented research, epidemiology and outcomes and effectiveness research. His research unites medicine and public health with the goals of saving and improving quality of human lives. It involves the knowledge of fundamental discoveries in biology and clinical medicine to advance the health of patients and populations affected by kidney disease. Dr. Powe earned his medical degree at Harvard Medical School and his master’s in public health at Harvard School of Public Health. He completed a residency, was a Robert Wood Johnson Clinical Scholar, and completed his master’s in business administration at the University of Pennsylvania.
John Wagner, MD, MBA, a nephrologist who directed a large academic dialysis program for 20 years in Queens, New York, has been a faculty member of several New York medical schools, currently SUNY Downstate in Brooklyn, New York, and for 20 years has served in various capacities with the ESRD Network of New York (Network 2), supporting its efforts to improve the quality of care rendered to patients with ESRD in New York. He is currently the associate medical director and patient safety officer at NYC Health + Hospitals/Kings County, allowing him to circle back after many years to the sister institution of the one that provided him with his foundational experience as a doctor in training. His research interests have included novel therapeutic agents in ESRD and metabolic bone disease. This past year he was delighted assumed the newly defined role of nephrology service line lead for the 11 hospital, 4 outpatient dialysis center system, which will afford a unique opportunity to explore how to best identify and manage the CKD of a population with significant socio-economic challenges.